SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...

UC San Diego's Moores Cancer Center has received a $1 million donation from pharmaceutical giant Pfizer to support early ...

Three additional posters highlighting the potential for broad therapeutic applications of azenosertib as both a single agent and combination therapy as shown in preclinical models SAN DIEGO, March 25, ...

with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a ...

Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical ... Zentalis has operations in San Diego. This press release contains forward-looking statements within the meaning of the U.S.

The posters can be accessed through the “Supporting Publications” tab on the “Our Approach” section of the Zentalis website at the time of each presentation’s starting session. Azenosertib is a novel, ...

The posters can be accessed through the“Supporting Publications” tab on the“Our Approach” section of the Zentalis website at the time of each presentation's starting session. Azenosertib ...

Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical ... Zentalis has operations in San Diego. This press release contains forward-looking statements within the meaning of the U.S.

Zentalis Pharmaceuticals, Inc. (ZNTL) reported Q3 EPS of ($0.96), $0.26 better than the analyst estimate of ($1.22).